Immunitybio announces fda submissions of supplemental bla for nmibc papillary disease and for expanded access of anktiva® to treat lymphopenia

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a leading immunotherapy company, today announced that it has completed multiple submissions to the fda including an sbla for bcg-unresponsive nmibc in papillary disease and an eap for anktiva® (nogapendekin alfa inbakicept-pmln) for the treatment of lymphopenia. supplemental biologics license application (sbla): in q1, immunitybio completed the submission to the fda of an sbla for the use of anktiva plus bcg in bcg-unrespon.
IBRX Ratings Summary
IBRX Quant Ranking